Cargando…
Switching from branded to generic glatiramer acetate: 15-month GATE trial extension results
BACKGROUND: Open-label 15-month follow-up of the double-blind, placebo-controlled Glatiramer Acetate clinical Trial to assess Equivalence with Copaxone(®) (GATE) trial. OBJECTIVE: To evaluate efficacy, safety, and tolerability of prolonged generic glatiramer acetate (GTR) treatment and to evaluate e...
Autores principales: | Selmaj, Krzysztof, Barkhof, Frederik, Belova, Anna N, Wolf, Christian, van den Tweel, Evelyn RW, Oberyé, Janine JL, Mulder, Roel, Egging, David F, Koper, Norbert P, Cohen, Jeffrey A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700775/ https://www.ncbi.nlm.nih.gov/pubmed/28090798 http://dx.doi.org/10.1177/1352458516688956 |
Ejemplares similares
-
Follow-on glatiramer acetate
por: Cohen, Jeffrey A., et al.
Publicado: (2018) -
Demonstration of Equivalence of Generic Glatiramer Acetate and Copaxone(®)
por: Lipsky, Peter, et al.
Publicado: (2021) -
Demonstration of Biological and Immunological Equivalence of a Generic Glatiramer Acetate
por: D’Alessandro, Josephine, et al.
Publicado: (2017) -
Comparing the Biological Impact of Glatiramer Acetate with the Biological Impact of a Generic
por: Towfic, Fadi, et al.
Publicado: (2014) -
Tolerability and Safety Profile of a New Brand-Generic Product of Glatiramer Acetate in Iranian Patients with Relapsing-Remitting Multiple Sclerosis: An Observational Cohort Study()
por: Abolfazli, Roya, et al.
Publicado: (2018)